Trial Profile
An Open-label, Multicenter, Efficacy and Safety Pilot Study of 6-month Canakinumab Treatment With up to 6-month Follow-up in Patients With Active Hyper-IgD Syndrome (HIDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Hereditary autoinflammatory diseases; Hyperimmunoglobulinaemia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 May 2017 Primary endpoint (Number of Flares Per Participant During Historical Period and Treatment Period) has been met.
- 08 May 2017 Results published in the Arthritis and Rheumatology
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.